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Abstract
Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer associated with high mortality. Merkel cell
polyomavirus (MCV), discovered in 2008, is associated with ~80% of MCC. The MCV large tumor (LT) oncoprotein
upregulates the cellular oncoprotein survivin through its conserved retinoblastoma protein-binding motif. We confirm
here that YM155, a survivin suppressor, is cytotoxic to MCV-positive MCC cells in vitro at nanomolar levels. Mouse
survival was significantly improved for NOD-Scid-Gamma mice treated with YM155 in a dose and duration dependent
manner for 3 of 4 MCV-positive MCC xenografts. One MCV-positive MCC xenograft (MS-1) failed to significantly
respond to YM155, which corresponds with in vitro dose-response activity. Combination treatment of YM155 with
other chemotherapeutics resulted in additive but not synergistic cell killing of MCC cell lines in vitro. These results
suggest that survivin targeting is a promising therapeutic approach for most but not all MCV-positive MCCs.
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Introduction
Merkel cell carcinoma (MCC) is an aggressive non-
melanoma skin cancer. Current therapies for MCC include
surgical excision combined with radiation treatment [1,2,3,4].
However, the prognosis for patients with MCC is relatively
poor, with a 2-year survival of 11% at stage IV (metastatic
disease), a 5-year survival of 52% at stage III (disease with
abnormal lymph nodes), and a 5-year survival of 67-81% at
stages II-I (local disease) [2]; 25-30% of patients will already
present with distal metastasis or lymph node abnormalities at
the time of diagnosis [2,5]. Recent increases in MCC incidence
[6,7,8,9] and association with immunocompromised conditions
[7,10,11] prompted a search for an underlying viral cause. A
novel human polyomavirus was discovered in MCC using
digital transcriptome subtraction (DTS), a computationally-
directed search for viral transcript sequences expressed in
tumor tissues [12]. Merkel cell polyomavirus (MCV) has since
been detected in ~80% of MCCs by multiple groups worldwide
(reviewed by Kuwamoto [13]). MCV is found clonally integrated
in MCC tumor cells, indicating that infection occurs prior to
carcinogenesis [12,14,15,16].
Two viral proteins, MCV large tumor antigen (LT) and small
tumor antigen (sT), contribute to MCC oncogenesis.
Knockdown of both LT and sT results in cell death of MCV-
positive MCC cell lines [17,18,19], as well as tumor regression
in MCV-positive MCC xenografts [19]. Knockdown of sT alone
results in growth arrest of MCC cell lines [19]. In all tumors
examined to date, MCV LT is truncated by mutations that
disrupt the LT helicase domain and render the virus replication
incompetent [14,16]. The C-terminus of LT has recently been
associated with anti-proliferative properties [20,21], which may
provide a selective pressure to disrupt this region of LT during
tumor initiation. Tumor-derived LT proteins, however, maintain
a functional and conserved retinoblastoma protein (Rb) binding
motif [12,14,15].
DTS analysis revealed that cellular genes are differentially
expressed in MCV-positive MCCs, relative to MCV-negative
MCCs. mRNAs for the cellular oncoprotein survivin were found
to be seven-fold higher in virus positive, compared to virus
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negative MCC tumors [22]. This was not confirmed by a
microarray analysis, suggesting either variability in tumors or
technical differences in tumor dissection and mRNA detection
[23]. Expression of both tumor-derived and wild-type MCV LT
in BJ fibroblasts induces survivin expression unless the Rb-
binding motif is mutated. Both transcript and protein levels of
survivin decrease upon T antigen knockdown in several MCV-
positive MCC cell lines, and knockdown of survivin results in
cell death [22]. This has recently been confirmed by Xie et al
[24]. While LT induction of survivin may be required for MCV-
positive MCC cell survival, additional signaling pathways are
also likely to be targeted by MCV LT [25].
A small molecule inhibitor of the survivin promoter, YM155
[26], was initially identified using a promoter luciferase reporter
assay [26]. YM155 was able to diminish luciferase activity in a
survivin promoter dependent context without cellular toxicity
[26]. YM155 has since been shown to bind interleukin
enhancer binding factor 3 (ILF3) [27], disrupting the ILF3/p54nrb
transcriptional complex at the survivin promoter, decreasing
E2F1/2-mediated transcriptional activation of survivin [28].
YM155 antitumor activity has been demonstrated using a
variety of cancer cell lines both in vitro and in mouse xenograft
studies [29-35], and tested in phase I and II clinical trials for
multiple malignancies [36-41]. Exploiting the apparent
dependence of MCV-positive MCCs on survivin, YM155 was
previously tested both in vitro and in vivo for MCC-specific cell
killing with promising results [22].
We show here that YM155 is a potent inhibitor of MCC
progression for most, but not all, MCV-positive MCC xenografts
in NSG (non-obese diabetic, severe combined
immunodeficient-gamma interleukin 2 receptor null) mice.
While YM155 is toxic to MCV-positive MCC cells in vitro, the
combination of YM155 with other common chemotherapeutic
agents results in additive, but not synergistic, killing of MCV-
positive MCC cells. Despite prolonged suppression of MCC
growth in responsive mice, most mice were ultimately
euthanized due to progressive MCC disease during YM155
treatment. Our results suggest that survivin targeting by small
molecule inhibitors may be a promising approach to MCC
therapy.
Materials and Methods
Ethics Statement
All animal studies were performed with approval from the
Animal Ethics Committee of the University of Pittsburgh
(Institutional Animal Care and Use Committee Protocol
#12020149). Tumor cell line injections, monitoring, and
euthanasia were carried out under conditions to minimize
suffering and in compliance with guidelines of the Hillman
Cancer Center Animal Facility accredited by the Association for
the Assessment and Accreditation for Laboratory Animal Care
International.
Cell Lines and Tissue Culture
The MCC cell lines MKL-1 [42,14], MS-1 [43], MKL-2 [44],
and WaGa (gift of J. Becker [19]) were cultured in RPMI 1640
with 10% fetal calf serum, and primary human fibroblasts, BJ
(American Type Culture Collection), were cultured in
Dulbecco’s modified Eagle’s medium with 10% fetal calf serum,
as described previously [22,43]. All cells were maintained at
37°C in humidified air containing 5% CO2.
NOD-Scid-Gamma Mice
The animals used for these studies are as described
previously [22]. NSG female mice [45], strain #005557
(Jackson Laboratory), were received at 6-weeks of age and
maintained in a specific, pathogen-free environment at the
Hillman Cancer Center Mouse Facility, University of Pittsburgh,
for at least one week prior to cell line injection. All animal
studies were performed with approval from the Animal Ethics
Committee of the University of Pittsburgh (Institutional Animal
Care and Use Committee Protocol #12020149).
Xenografts and Treatment
MCC xenografts were generated as previously described
[22]. MCC cell lines were optimally grown at >90% cell viability
as determined by trypan blue dye exclusion. MCC cells were
washed with phosphate-buffered saline (PBS) and
resuspended at 2x107cells per 100uL in PBS and injected into
the right flanks of NSG mice. Tumor cell line injections were
carried out under isoflurane anesthesia to minimize suffering.
Treatment regimens began as individual animals developed
palpable tumors (~2mm x 2mm), as outlined in Figure 1. All
treatments followed a five day on, two day off regimen of daily
intraperitoneal (I.P.) injections. Three-week treatments ended
on day 19 of I.P. injection. Continuous treatments were carried
out until the animals reached the experimental endpoint. The
experimental endpoint was evaluated by tumor burden, with at
least one measurable diameter of 20mm, or by the presence of
multiple signs of distress (>20% weight loss, behavioral
changes, inactivity, or ruffled fur). Saline-treated mice were
injected with a fixed volume of 100uL 0.9% Sodium Chloride
USP Normal Saline (Nurse Assist) per injection. YM155 was
administered at either 2mg/kg, 4mg/kg, or 6mg/kg,
resuspended in 0.9% Sodium Chloride USP Normal Saline and
filter sterilized. Tumor volumes were measured three times
weekly and at the time of euthanization according to the
following formula: width2 x length ÷ 2. Mouse weights were
monitored at least once per week throughout the experiment.
Observations, including weight measurements, were recorded
daily on an individual mouse basis if signs of distress were
observed.
Statistical Analysis of Survival and Tumor Volume Data
Mixed-effects ANOVA was used for batch-adjusted times to
50% survival per cell line and treatment group, with 95%
confidence intervals. Pairwise comparisons between
treatments or between cell lines were estimated (with 95%
confidence intervals) by linear contrasts on the estimated
ANOVA parameters [46,47]. Between-batch variation was
taken into account for all analyses. Tumor volumes were
assessed for differential growth across treatment groups using
an extension to the piecewise linear hierarchical Bayesian
model [48] that accounts for batch effects. All analyses were
performed using SAS (SAS Institute), R (R Development Core
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Team) and JAGS software [49]. Average tumor growth kinetics
with 95% confidence intervals were estimated as described
previously [22]. Briefly, a delay in tumor growth (or re-growth) is
estimated by a hinge point, called nadir, where the volume at
nadir (α) is expressed as a log2(volume) and the time at nadir
(ρ) is expressed in days. An initial decrease in growth is
estimated as β1, where log2(volume) = α+β1*(ρ-day). Final
increase in tumor growth is estimated as β2, where
log2(volume) = α+β2*(day-ρ). These four parameters are
estimated for each animal and for each treatment and cell line.
Immunohistochemistry
Immunohistochemistry was performed as described
previously [15]. Tumor and/or normal mouse tissue was cut to
size for optimal formalin infusion (10% neutral-buffered
solution; Sigma) for at least 24hrs prior to paraffin embedding.
Paraffin embedding, preparation of unstained slides, and H&E
processing was performed by Research Histology Services at
the Thomas E. Starzl Transplantation Institute core facilities at
the University of Pittsburgh. Unstained slides were baked at
60°C for 1hr under vacuum. Deparafinization continued with
xylene treatment (2-3 incubations, 10min). Slides were
gradually rehydrated moving from 100% ethanol (2 incubations,
10min), to 95% ethanol (2 incubations, 10min), to 80% ethanol
with agitation, to 70% ethanol with agitation, and finally moving
to deionized water. Slides were treated with 3% hydrogen
peroxide to quench endogenous peroxidases, rinsed several
times with deionized water, and then placed in 1mM EDTA
pH8.0 for heat-induced epitope retrieval (125°C for 3min and
15s, followed by 90°C for 15s). After 45-60min of gradual
cooling, slides were briefly rinsed several times with deionized
water, rinsed with TBS (68mM NaCl, 10mM Tris pH7.5),
Figure 1.  MCC mouse xenograft treatment groups and experimental outline.  A) NSG mice were subcutaneously injected in
the right flank with 2x107 MCV-positive, MCC cells (MKL-1, MS-1, WaGa, or MKL-2). B) NSG mice were monitored for palpable
tumors (~2mm x 2mm) to determine start of treatment. C) Mice with palpable tumors were randomly assigned to either saline
treatment, YM155 treatment for 3-weeks at 2mg/kg, YM155 continuous treatment at 2mg/kg, or YM155 continuous treatment at
4mg/kg. Each week of treatment consisted of a single intraperitoneal injection per day for 5 days, followed by 2 days of rest.
doi: 10.1371/journal.pone.0080543.g001
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treated with Protein Block (DAKO) for 5min, and then incubated
with CM2B4 (15) primary antibody (diluted 0.5-1.5ug/mL) for
30min (PBS pH7.4, 1% BSA, 0.1% gelatin, 0.5% Triton-X-100,
0.05% sodium azide). Slides were washed 3 times with
agitation in TBS. Secondary mouse-HRP antibody (Mouse
Envision Polymer; DAKO) was incubated on the slides for
30min. Slides were again washed 3 times with agitation in TBS.
Colorimetric detection with 3,3-diaminobenzidine and
chromagen was quenched with deionized water. Slides were
counter-stained with Mayer’s hemotoxylin, Lillie’s modification
(DAKO), rinsed several times in tap water, blued in 1% lithium
carbonate, rinsed several times in tap water, and then
dehydrated through 95% ethanol (twice with agitation) to 100%
ethanol (twice with agitation). Slides were incubated twice in
xylene for 5min and coverslips were adhered using Permount
(Fisher Scientific).
Chemotherapeutic Compounds
YM155 was purchased from Active Biochemicals Ltd.
Docetaxel, carboplatin, etoposide, topotecan HCl, and
bortezomib were provided by the NCI/DTP Open Chemical
Repository (http://dtp.cancer.gov).
Dose-Response Studies
Dose-response studies were performed as previously
described [22]. Briefly, 6000 cells were seeded per well in 384
well plates at a volume of 50uL and allowed to incubate
overnight at 37°C in a 5% CO2 humidified chamber. A log
range of drug concentrations from 10-4 to 10-10 was
resuspended in culture medium (with or without a fixed amount
of YM155) at 3X concentration and then added at a volume of
25uL. After 48 hours further incubation in a humidified
chamber, cells were treated with 25uL CellTiter-Glo
Luminescent reagent (Promega) and cell viability was
measured as per manufacturer’s instructions. No-drug control
wells served as normalization controls per cell line. Each
concentration per cell line was plated in triplicate. Three or
more biological replicates per cell line were tested with YM155
alone, two or more biological replicates were tested with all
other single drugs, and combination studies were tested
independently with 3nM YM155, with representative analysis at
3nM YM155 combination shown. Empty wells were used to
separate different cell lines and treatment groups to reduce
error from luminescent bleed-over. EC50 values were
calculated from a four-parameter logistic equation fit to the
surviving proportions of cells per dose.
Results
MCV-Positive MCC Cell Lines Injected Subcutaneously
in NSG Mice Have Variable Growth Rates
NSG mice were injected with MCV-positive MCC cell lines
(Figure 1A) and were monitored for tumor growth, weight
(Figure S1 in File S1), and overall health. The length of time
between cell line injection and detection of palpable tumors
varied over a range for each cell line (Figure 2). Overall, the
time until 50% of mice had detectable, palpable tumors after
cell line injection was shortest with MKL-1 xenografts, followed
by WaGa, MKL-2, and finally MS-1.
Once palpable tumors were detected (Figure 1B), NSG mice
were intraperitoneally (I.P.) injected (once per day for five days,
followed by two days of rest, Figure 1C) with either saline
treatment, 2mg/kg YM155 treatment for three weeks, or were
continuously treated with YM155 (2mg/kg or 4mg/kg) until the
tumor attained a diameter of 20mm or the mouse exhibited
multiple signs of distress. YM155 at 6mg/kg was tested in two
mice, but both mice had >20% weight loss and additional signs
of distress (ruffled fur, inactivity, and behavioral changes)
within the first week of treatment and were euthanized (as per
Institutional Animal Care and Use Committee protocol
#12020149). Mice receiving saline treatment or YM155
treatment at 2mg/kg do not lose weight (Figure 3A and 3B,
respectively) or show signs of distress, whereas mice receiving
YM155 at 4mg/kg lose weight (Figure 3C) and display minimal
signs of distress (only ruffled fur, normal behavior). This toxicity
dissipates after the first 1-2 weeks of treatment (Figure 3C).
Thus, 4mg/kg YM155 is the maximum tolerated dose in NSG
mice when administered by single daily I.P. injection.
Survival of mice with MCC xenografts is prolonged from the
start of treatment by increasing YM155 duration of treatment,
as well as by increasing the dosage of YM155, in a cell line
dependent manner
Estimated mean survival times with 95% confidence intervals
are presented in Table S1 in File S3 and Figure 4A according
to treatment group and cell line. Batch variations from
independent replicates per treatment group and cell line were
taken into account for the reported statistical analyses.
Comparisons of estimated mean survival times across
treatment groups or across cell lines are indicated in Table S2
in File S3. Figure 4B shows a Kaplan-Meier survival curve for
MKL-1 xenografts treated for a single 3-week course (2mg/kg
YM155) or continuously until sacrifice (data from this figure
include MKL-1 bearing mice treated in preliminary studies,
published in [22]). Extending the duration of YM155 treatment
prolongs survival (relative to saline or 3-week treatment,
P<0.0001; Table S2 in File S3), which is prolonged further by
doubling the YM155 dose to 4mg/kg (relative to all treatment
arms, P<0.0001; Table S2 in File S3).
We find EC50 values for YM155 in vitro range from 1.5nM to
12nM for different MCV-positive MCC cell lines (Table S3 in
File S3), which are nearly identical to those previously
described [22]. MKL-1 and MS-1 are at opposite ends of this
range, respectively. MS-1 was tested in mice to assess the
degree of response to YM155 in vivo. Mice were treated with
either saline, 2mg/kg YM155 continuously, or 4mg/kg YM155
continuously as outlined in Figure 1. In contrast to MKL-1,
Figure 4C and Table S2 in File S3 show that MS-1 does not
significantly respond to YM155 treatment in vivo, despite
extended duration of treatment or increased dosage. This data
is consistent with a lack of overall response to YM155 in MS-1
bearing mice, which was observed in our previous pilot
comparison [22] (mice were not included here because of
treatment protocol differences). Two other MCV-positive MCC
cell lines, WaGa and MKL-2 (Figures 4D-4E and Table S2 in
File S3), were also re-evaluated for YM155 response in vitro.
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While our initial evaluation of WaGa in vitro response to YM155
is comparable to our previous data (6.0nM and 8.5nM [22],
respectively), we determined with additional biological
replicates that MKL-2 in vitro response to YM155 is more
intermediate to MKL-1 and MS-1, with an EC50 value of 5.8nM
(previously reported at 12.2nM [22]) (Table S3 in File S3). Both
WaGa and MKL-2 xenografts responded in vivo to YM155
(4mg/kg) relative to saline treatment (P=0.0034 and P<0.0001,
respectively; Table S2 in File S3). The comparisons of
estimated mean survival on the 4mg/kg YM155 continuous
treatment arm indicate that survival is prolonged greatest
relative saline treatment for mice with MKL-1 xenografts,
followed by MKL-2, WaGa, and finally MS-1, which do not have
prolonged survival (Table S2 in File S3).
Tumor Shrinkage and Delay of Re-Growth (Regression),
and/or Slower Growth Rate Is Observed upon YM155
Treatment (Relative to Saline) in Three of Four MCC
Xenografts
Average tumor growth kinetics per cell line and treatment
arm are reported in Table S4 in File S3. Tumor volume data for
all 193 mice are reported in Figure 5. Delay of tumor re-growth
was significant in all YM155 treatment arms of mice with MKL-1
xenografts (Figure 5A), relative to saline: 2mg/kg YM155
treatment for three weeks (8.6±2.5 days); 2mg/kg continuous
YM155 treatment (15.8.6±3.2 days); and 4mg/kg continuous
YM155 treatment (29.9±4.0 days) (Table S4 in File S3). The
delay in re-growth was significantly greater in the 4mg/kg arm
than the 2mg/kg arm (P<0.05). After the initial delay, final tumor
growth rate of MKL-1 xenografts in mice treated continuously
Figure 2.  Time-to-Palpability.  The length of time lapsed after initial cell line injection to detection of palpable tumors (~2mm x
2mm) is indicated for each of the four MCC cell lines tested (MKL-1, WaGa, MKL-2, and MS-1).
doi: 10.1371/journal.pone.0080543.g002
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Figure 3.  Mouse weights by treatment regimen.  Average mouse weights with standard deviations are reported according to
treatment regimen, where weights were normalized to day zero of treatment (100%): A) mouse weights on saline, continuous-
treatment (green line); B) mouse weights on 2mg/kg YM155, continuous-treatment (purple line); and C) mouse weights on 4mg/kg
YM155, continuous-treatment (orange line). Mouse weights were adjusted to remove the weight of tumors prior to normalization.
Weights from mice with significant liver metastases were not included as metastatic-tumor weights could not be determined during
the course of treatment.
doi: 10.1371/journal.pone.0080543.g003
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with YM155 (2mg/kg or 4mg/kg) was slower than mice treated
with YM155 for 3-weeks or mice treated with saline (both P-
values <0.05). Final tumor growth rates in mice treated
continuously at either 2mg/kg or 4mg/kg doses were
comparable (Table S4 in File S3).
We next evaluated tumor growth response in MS-1 bearing
mice. In our prior studies there was some noted response in
tumor volume at the end of a three-week, 2mg/kg treatment
period with YM155, relative to saline. However, this data
corresponded to only 5 mice with no significant difference in
overall survival [22]. In our current studies with increased
duration of treatment and dosage, there was no shrinkage in
tumor volume, delay of tumor re-growth, or reduction in growth
rate observed in mice with MS-1 xenografts comparing saline
treatment to YM155 treatment at either 2mg/kg or 4mg/kg
(Figure 5B and Table S4 in File S3). WaGa xenografts in mice
treated continuously with 4mg/kg YM155 grew slower than
mice treated with saline (P<0.05), but there was no evidence of
initial tumor shrinkage or delay of re-growth in these mice
(Figure 5C and Table S4 in File S3). There was evidence of
initial tumor shrinkage in YM155-treated mice with MKL-1
(Figure 5A) and MKL-2 (Figure 5D) xenografts (all P-values
<0.05), but the absolute amount of shrinkage was small (Table
S4 in File S3). The delay of tumor re-growth was significantly
longer in mice with MKL-1 xenografts than in mice with MKL-2
xenografts (P<0.05); tumor shrinkage and delayed tumor re-
Figure 4.  Kaplan-Meier curves of multiple MCC mouse xenograft models on different treatments.  A) Estimated survival
means and 95% confidence intervals are reported along compressed survival summaries per cell line and treatment arm, where
open circles correspond survival of individual mice. B) Mice with MKL-1 xenografts exhibit significantly prolonged survival (****P <
0.0001) on any of the three YM155 treatment groups (3-weeks at 2mg/kg = red; continuous treatment at 2mg/kg = purple;
continuous treatment at 4mg/kg = orange) relative to saline treatment (green). Increasing the duration of YM155 treatment from 3-
weeks to continuous treatment at the 2mg/kg dose significantly prolongs survival (****P < 0.0001). Increasing the dose of YM155
from 2mg/kg to 4mg/kg on continuous treatment significantly prolongs survival (****P < 0.0001). C) Mice with MS-1 xenografts do
not exhibit prolonged survival with YM155 continuous treatment (either at 2mg/kg or 4mg/kg) relative to saline treatment (NS = not
significant). One mouse on saline treatment spontaneously regressed for over 5-weeks and was euthanized early (as indicated by
x). D) Mice with WaGa xenografts exhibit significantly prolonged survival (**P = 0.0034) with continuous YM155 treatment at 4mg/kg
relative to saline treatment. E) Mice with MKL-2 xenografts exhibit significantly prolonged survival (****P < 0.0001) with continuous
YM155 treatment at 4mg/kg relative to saline treatment. Two mice did not reach the final 20mm tumor dimension by day 105 and
were euthanized early (as indicated by ##).
doi: 10.1371/journal.pone.0080543.g004
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growth correlate with a regression period in which >20% of
mice no longer had palpable tumors (Table S4 in File S3,
Figure 5A and 5D, marked by asterisks). However, all mice
were eventually euthanized due to progressive disease. Thus,
while YM155 continuous treatment at 4mg/kg prolongs survival
in NSG mice with three of the four MCC xenografts, this
treatment regimen does not eradicate tumor cells.
MCV-Positive MCC Xenograft Mouse Models Develop
Metastases at Different Locations in a Cell Line
Dependent Manner
MKL-1, MS-1, and WaGa cell lines are each derived from
metastatic lesions [18,42,43]; the site of MKL-2 derivation is
unknown [44]. Common sites of metastasis include skin, lymph
nodes, liver, lung, bone, and brain (reviewed by Eng et al [4]).
Necropsy was performed on each mouse reaching
experimental endpoint to assess the metastatic capability of
each cell line in our mouse xenograft models. Mice with MKL-1,
MS-1, or MKL-2 xenografts developed at least one or more
metastases. LT-staining of primary xenograft tumors was
Figure 5.  Tumor volume response to YM155 is dose, duration, and cell line dependent.  Tumor volumes (mm3) are reported
on a Log2 scale according to treatment group. Non-palpable (NP) tumors are indicated at baseline corresponding to tumor
regression. A) Tumor volumes of MKL-1 xenografts undergo an initial regression period with YM155 treatment where >20% of mice
lack palpable tumors (as indicated by *), which is extended with increased dose and duration of YM155 treatment. Overall tumor
growth rate is reduced with increased YM155 duration and dosage. A total of 9 mice were euthanized before a diameter of 20mm
was measured on the primary tumor due to distress associated with liver metastasis (as indicated by o). B) Tumor volumes of MS-1
xenografts are unaffected by YM155 treatment. A spontaneous regression was observed on saline treatment (as indicated by x). C)
Tumor volumes of WaGa xenografts do not undergo an initial regression, but have a reduced growth rate. D) Tumor volumes of
MKL-2 xenografts undergo an initial regression period with YM155 treatment where >20% of mice lack palpable tumors (as
indicated by *). Overall tumor growth rate is reduced on YM155 treatment relative to saline treatment. Two mice did not reach the
final 20mm tumor dimension by day 105 (as indicated by #).
doi: 10.1371/journal.pone.0080543.g005
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confirmed for at least one mouse per treatment group, per cell
line (data not shown). Metastatic lesions also stained positive
for LT, confirming a MCC origin (Figure 6 and Figure S2 in File
S2);
MCC metastases occurred in the liver of 18/117 mice with
MKL-1 xenografts; this subset corresponds to 27% of MKL-1-
injected mice that survive past day 25. Diameters of metastatic
lesions were highly variable. In 9/117 instances, liver
metastasis resulted in distress requiring euthanization of mice
before primary tumor diameters of 20mm were measured
(Figure 5A, marked by open circles). Both MKL-1 xenograft
primary tumors (Figure 6A-6B) and liver metastases (Figure
6C-6D) contain nuclear staining for MCV-LT. Dual MKL-2
metastases occurred along the urogenital tract in 1/20 mice
with separate lesion diameters of 12mm and 13mm. LT-
staining in urogenital metastases was similar to staining of
MKL-2 xenograft primary tumors (Figure S2A-S2D in File S2).
MKL-2-derived MCV-LT is truncated [12,18] prior to the nuclear
localization signal, or NLS [50], thus staining for LT is not
restricted to the nucleus as with MKL-1 or MS-1. In one
instance, a MS-1 primary tumor regressed spontaneously
under saline treatment for more than 5 weeks (Figure 5B,
marked by x), but necropsy revealed a 3mm-diameter
subcutaneous metastasis on the abdomen. This metastasis
was confirmed to stain for MCV-LT, similar to MS-1 xenograft
primary tumors (Figure S2E-S2H in File S2). Local invasion to
surrounding tissues within the abdominal cavity, resulting in
tumors of ~30mm diameter, was also observed in three MS-1
xenografts. WaGa xenograft primary tumors stain positive for
LT (Figure S2I-S2J in File S2). WaGa-derived MCV-LT is
truncated within the NLS [18,50], thus staining of LT is not
restricted to the nucleus. WaGa-injected mice did not develop
any metastases.
Combination Drug Treatments with YM155 Act
Additively, But Not Synergistically, to Reduce MCC Cell
Line Viability In Vitro
YM155 was tested alone (Figure 7A) and in combination with
other chemotherapeutic agents to identify a treatment strategy
that may kill MCC cells synergistically. Bortezomib, docetaxel,
carboplatin, etoposide, and topotecan were tested alone or in
combination with a fixed concentration of YM155 (Figure 7B-I,
and Table S3 in File S3). Bortezomib is a proteasomal inhibitor
that has been shown previously to efficiently kill MCC cells at
sub-micromolar concentrations [22]. However, primary human
fibroblasts, BJ, are also efficiently killed by bortezomib
treatment (Figure 7B-C). Docetaxel was previously tested in
melanoma xenografts with YM155 to induce cancer-specific
mitotic catastrophe and cell death [35]. Docetaxel treatment
does not decrease cell viability of MCC cell lines (Figure 7D-E).
Carboplatin, a platinum-based chemotherapeutic, also does not
decrease cell viability of MCC cell lines (Table S3 in File S3).
Etoposide, a topoisomerase type II inhibitor, with or without
carboplatin (data not shown), decreases cell viability of MCC
cell lines at micromolar concentrations (Figure 7F-G).
Topotecan, a topoisomerase type I inhibitor, decreases cell
viability at sub-micromolar concentrations (Figure 7H-I).
However, none of these chemotherapeutic agents decrease
cell viability of MCC cells in a synergistic manner when
combined with YM155—the effect is merely additive. EC50
values with 95% confidence intervals are reported in Table S3
in File S3.
Discussion
In this study we assessed the sensitivity of four MCV-positive
MCCs to a small-molecule survivin inhibitor, YM155. Three of
the four xenografts responded to YM155 treatment. YM155
efficacy is enhanced by extending the duration of treatment as
well as by increasing YM155 dosage. However, the degree of
YM155 efficacy is cell line dependent. Overall response to
YM155 in MKL-1 xenografts, as well as a lack of overall
survival to YM155 in MS-1 xenografts, is consistent with our
previous observations [22]. Response to YM155 in vivo (Table
S2 in File S3) reflects YM155 response in vitro (Figure 7A);
WaGa and MKL-2 xenografts respond to YM155 treatment
intermediately compared to MKL-1 and MS-1 when assessing
in vivo estimated survival data between YM155 4mg/kg
continuous treatment and saline treatment (Table S2 in File
S3), and they also have intermediate EC50 values determined
from in vitro cell viability data (Figure 7A). MKL-1 is the most
sensitive to YM155 both in vivo and in vitro, whereas MS-1 is
the least sensitive to YM155 in vitro and does not respond to
YM155 in vivo. While relatively non-toxic, YM155 has been
withdrawn from clinical development (Ann Keating, Astellas
Corporation, pers. comm.); our preclinical findings suggest that
survivin inhibition is a promising therapeutic approach for MCV-
positive MCC.
For MCC xenografts, regression, growth rate, and even
metastatic escape are highly cell line dependent. Liver
metastasis was only observed with MKL-1 xenografts, and
metastasis was only observed after survival was significantly
prolonged with YM155 treatment. While WaGa does not
undergo regression or even tumor shrinkage upon YM155
treatment, survival was significantly prolonged relative to saline
treatment owing to a reduced tumor growth rate. Why MCC
xenografts stop responding to YM155 treatment and what
determines overall response to YM155 for a given MCC cell
line remains unknown.
Previous studies using MCV-positive MCC cell lines
identified bortezomib as a potent in vitro chemotherapeutic, but
not in vivo [22]. Topoisomerase type I and type II inhibitors
were also shown to induce death of MCC cell lines [22].
Although we again verified in vitro efficacy of bortezomib,
etoposide, and topotecan, none of these agents act
synergistically with YM155 treatment—the effect is only
additive. However, this may not exclude the possibility that
combination therapy of topoisomerase inhibitors with survivin
inhibitors will prove beneficial in future studies.
Survivin Inhibition in Human MCV+ MCC Xenografts
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e80543
Figure 6.  Immunohistochemistry of MCV-LT in a MKL-1 xenograft primary tumor and a liver metastasis.  Shown are paired
hemotoxylin & eosin (H&E) stained slides and adjacent sections stained with CM2B4, the MCV-LT antibody (LT-IHC), in mice with
MKL-1 xenografts: A) MKL-1 xenograft primary tumor, H&E; B) MKL-1 xenograft primary tumor, LT-IHC; C) MKL-1 xenograft liver
metastasis, H&E; and D) MKL-1 xenograft liver metastasis, LT-IHC. MKL-1 cells contains nuclear staining of LT, consistent with an
intact nuclear localization signal (NLS). Original magnification = 200X; insets = 600X.
doi: 10.1371/journal.pone.0080543.g006
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Figure 7.  Various chemotherapeutics combined with YM155 induce MCC cell death in an additive manner, in
vitro.  CellTiter-GLO assays were performed using multiple MCC cell lines as well as the control primary human fibroblast, BJ.
Corresponding dose-response curves are shown for the following chemotherapeutic agents and drug combinations: A) YM155; B)
Bortezomib; C) Bortezomib + 3nM YM155; D) Docetaxel; E) Docetaxel + 3nM YM155; F) Etoposide; G) Etoposide + 3nM YM155 H)
Topotecan; and I) Topotecan + 3nM YM155.
doi: 10.1371/journal.pone.0080543.g007
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Supporting Information
File S1.  File includes Figure S1. Figure S1: Mouse weights
prior to treatment. Mouse weights were recorded at least once
weekly upon arrival and at greater intervals after cell line
injection and/or upon signs of distress. Average mouse weights
with standard deviations (black line) prior to treatment are
reported, with the final weight record adjusted to remove the
newly palpable (~2mm x 2mm) tumor volume. Maximum (red-
dashed line) and minimum (blue-dashed line) mouse weights
are also indicated.
(TIF)
File S2.  File includes Figure S2. Figure S2:
Immunohistochemistry of MCV-LT in MCC primary tumors and
metastases. Shown are paired hemotoxylin & eosin (H&E)
stained slides and adjacent sections stained with CM2B4, the
MCV-LT antibody (LT-IHC), in mice with MCC xenografts: A)
MKL-2 xenograft primary tumor, H&E; B) MKL-2 xenograft
primary tumor, LT-IHC; C) MKL-2 xenograft urogenital
metastasis, H&E; D) MKL-2 xenograft urogenital metastasis,
LT-IHC; E) MS-1 xenograft primary tumor, H&E; F) MS-1
xenograft primary tumor, LT-IHC; G) MS-1 xenograft
subcutaneous metastasis, H&E; H) MS-1 xenograft
subcutaneous metastasis, LT-IHC; I) WaGa xenograft primary
tumor, H&E; and J) WaGa xenograft primary tumor, LT-IHC.
MS-1 cells contain nuclear staining of LT, consistent with an
intact nuclear localization signal (NLS). Both MKL-2 and WaGa
lack an intact NLS, thus LT staining is not restricted to the
nucleus. Original magnification = 200X; insets = 600X.
(TIF)
File S3.  File includes Tables S1, S2, S3, and S4. Table S1:
Estimated Mean Survival Statistics. Mean estimated survival
statistics were calculated for each MCC xenograft and
treatment arm. C.I. = confidence interval. Table S2:
Comparative Survival Statistics. Different MCC xenografts and
treatment arms were cross-compared to determine differences
in estimated survival. Pr = probability; ****P<0.0001;
***P<0.001; **P<0.01; *P<0.1; NS = not significant. Table S3:
EC50 Values (M). MCC cell lines were evaluated for cell
viability over a range of different concentrations of
chemotherapeutic agents, where EC50 values are reported.
C.I. = confidence interval; N.D. = not determined; N.S.C. = non-
sigmoidal curve, value cannot be determined. Table S4:
Average Tumor Growth Kinetics. Tumor volumes were
assessed for differential growth across treatment groups using
an extension to the piecewise linear hierarchical Bayesian
model that accounts for batch effects. A delay in tumor growth
(or re-growth) is estimated by a hinge point, called nadir, where
the volume at nadir (α) is expressed as a log2(volume) and the
time at nadir (ρ) is expressed in days. An initial decrease in
growth is estimated as β1, where log2(volume) = α+β1*(ρ-day).
Final increase in tumor growth is estimated as β2, where
log2(volume) = α+β2*(day-ρ). The mean estimates and 95%
confidence intervals are reported for these four parameters for
each treatment and cell line. Corresponding regression periods
(range, in days) where >20% of mice no longer had palpable
tumors is indicated where appropriate. α = Log2 Tumor Volume
at Nadir; β1 = Pre-Nadir Slope (Decreasing); β2 = Post-Nadir
Slope (Increasing); ρ = Time at Nadir; Reg. = Regression; Std.
Err. = Standard Error; C.I. = Confidence Interval; and N/A = Not
Applicable.
(XLSX)
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